Smiths Detection Equips NATO With Vehicle Scanning Technology in Luxembourg
16.3.2021 11:00:00 EET | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has successfully completed the delivery and installation of a mobile high-energy inspection system trailer, the HCVM XT, at the NATO Support and Procurement Agency (NSPA) in Capellen, Luxembourg.
The NSPA site requires all external construction vehicles, and other equipment providers, to be scanned for potential threats that enter the site such as incendiary and explosive devices, radiological materials, weaponry and unauthorized surveillance or covert equipment.
Smiths Detection’s HCVM XT X-ray screening system quickly and efficiently screens for threats at the NSPA site while meeting the most demanding international security-screening requirements with a minimal size footprint and external infrastructure. The HCVM XT has a throughput of up to 25 vehicles an hour in mobile scanning mode and up to 100 trucks an hour in pass-through mode, with a steel penetration of up to 320mm, providing detailed X-ray images that also distinguishes organic and inorganic material. Smiths Detection is in the process of training NSPA agents to operate the product.
“We are delighted to be given the opportunity to supply the NSPA with this mobile high-energy inspection system and to be extending our work in Luxembourg, following on from our partnership with Luxembourg Customs using the same technology” said Jasper van Gend, Head of Market, Europe North & East. “Against a backdrop of increasingly complex threats, the NSPA is now well equipped to efficiently detect and deal with any potential threats coming onto the site utilising the HCVM XT, with its six scanning modes and adjustable scanning heights and angles.”
When equipped with the optional iCMORE radioactive-material detection system, the HCVM can carry out simultaneous X-ray inspections and an analysis to detect radioactive gamma and neutron materials.
ENDS
About HCVM XT:
https://www.smithsdetection.com/products/hcvm-mobile-x-ray-systems-smiths-detection/
About Smiths Detection:
Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.
For more information visit http://www.smithsdetection.com.
About NSPA:
NATO Support and Procurement Agency (NSPA) brings together, in a single organization, acquisition, logistic, medical and infrastructural capabilities, operational and systems support and services to the NATO nations, NATO Military Authorities and partner nations.
As NATO's primary enabler, its mission is to provide effective and cost efficient multinational solutions to the Alliance, its 30 Nations and Partners. NSPA is a customer-funded agency, operating on a "no profit - no loss" basis.
As one of the three NATO Agencies, NSPA operates under North Atlantic Council-approved charters. The Agency is the executive body of the NATO Support and Procurement Organisation (NSPO), of which all 30 NATO nations are members. Those nations represented on the NSPO Agency Supervisory Board (ASB), provide strategic direction and guidance to NSPA and oversee its activities and performance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005075/en/
Contact information
Media Contacts:
FTI Consulting:
Tom Hufton/Georgina Reeves
sc.smithsdetection@fticonsulting.com, +44 (0)20 3727 1000
Smiths Detection:
Sophie Mills, Global Communications Manager
sophie.mills@smithsdetection.com, + 44 (0)73 8423 6474
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom